Nomura Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.99M | Buy |
56,831
+2,437
| +4% | +$329K | 0.02% | 491 |
|
|
2026
Q1 | $6.95M | Sell |
54,394
-1,304
| -2% | -$163K | 0.02% | 514 |
|
|
2025
Q4 | $6.79M | Hold |
55,698
| – | – | 0.02% | 534 |
|
|
2025
Q3 | $5.58M | Buy |
+55,698
| New | +$5.02M | 0.01% | 573 |
|
|
2025
Q2 | – | Sell |
-1,011
| Closed | -$82K | – | 1558 |
|
|
2025
Q1 | $82K | Hold |
1,011
| – | – | ﹤0.01% | 978 |
|
|
2024
Q4 | $91.1K | Sell |
1,011
-13,581
| -93% | -$1.32M | ﹤0.01% | 972 |
|
|
2024
Q3 | $1.44M | Buy |
+14,592
| New | +$1.43M | ﹤0.01% | 763 |
|
|
2024
Q1 | – | Sell |
-100
| Closed | -$8.93K | – | 1587 |
|
|
2023
Q4 | $8.93K | Hold |
100
| – | – | ﹤0.01% | 1497 |
|
|
2023
Q3 | $7.3K | Hold |
100
| – | – | ﹤0.01% | 1509 |
|
|
2023
Q2 | $8.32K | Hold |
100
| – | – | ﹤0.01% | 1516 |
|
|
2023
Q1 | $7.62K | Sell |
100
-16,500
| -99% | -$1.37M | ﹤0.01% | 1520 |
|
|
2022
Q4 | $1.38M | Hold |
16,600
| – | – | 0.01% | 760 |
|
|
2022
Q3 | $1.32M | Buy |
16,600
+16,500
| +16,500% | +$1.39M | 0.01% | 748 |
|
|
2022
Q2 | $4.95M | Hold |
100
| – | – | 0.03% | 453 |
|
|
2022
Q1 | $8.99K | Buy |
+100
| New | +$9.23K | ﹤0.01% | 1539 |
|
|
2020
Q1 | – | Sell |
-2,305
| Closed | -$220K | – | 976 |
|
|
2019
Q4 | $220K | Sell |
2,305
-64,995
| -97% | -$5.62M | ﹤0.01% | 926 |
|
|
2019
Q3 | $5.13M | Buy |
67,300
+1,200
| +2% | +$99.7K | 0.05% | 329 |
|
|
2019
Q2 | $5.8M | Hold |
66,100
| – | – | 0.06% | 291 |
|
|
2019
Q1 | $5.99M | Buy |
+66,100
| New | +$5.62M | 0.06% | 286 |
|
|
2018
Q4 | – | Sell |
-24,614
| Closed | -$1.98M | – | 942 |
|
|
2018
Q3 | $2.36M | Sell |
24,614
-7,776
| -24% | -$754K | 0.02% | 500 |
|
|
2018
Q2 | $3.08M | Sell |
32,390
-4,718
| -13% | -$434K | 0.03% | 422 |
|
|
2018
Q1 | $3.25M | Sell |
37,108
-7,509
| -17% | -$686K | 0.04% | 383 |
|
|
2017
Q4 | $3.79M | Buy |
+44,617
| New | +$3.74M | 0.04% | 334 |
|
|
2017
Q3 | – | Sell |
-31,448
| Closed | -$2.43M | – | 952 |
|
|
2017
Q2 | $2.43M | Hold |
31,448
| – | – | 0.03% | 409 |
|
|
2017
Q1 | $2.18M | Buy |
31,448
+2,460
| +8% | +$165K | 0.03% | 432 |
|
|
2016
Q4 | $1.72M | Hold |
28,988
| – | – | 0.03% | 475 |
|
|
2016
Q3 | $1.92M | Buy |
28,988
+16,731
| +137% | +$1.04M | 0.03% | 435 |
|
|
2016
Q2 | $663K | Sell |
12,257
-14,733
| -55% | -$807K | 0.01% | 747 |
|
|
2016
Q1 | $1.39M | Buy |
+26,990
| New | +$1.4M | 0.03% | 515 |
|
Other funds holding XBI
JFG
Nomura Asset Management's XBI Position: Q2 2026 in Review
Nomura Asset Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 4.5% in Q2 2026, buying an estimated $329K and bringing the position to 56,831 shares worth $8.99M. The position accounts for 0.02% of the portfolio, ranked #491.
Nomura Asset Management first reported a position in XBI in Q1 2016 and has held it in 29 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Nomura Asset Management held 56,831 shares of State Street SPDR S&P Biotech ETF worth $8.99M as of Q2 2026.
- Nomura Asset Management bought 2,437 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $329K.
- State Street SPDR S&P Biotech ETF made up 0.02% of Nomura Asset Management's portfolio in Q2 2026, its #491 holding.
- Nomura Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and has held it in 29 quarters since.
- 936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.